MaxCyte, Inc.

Production and provision of a platform technology for rapidly loading bioactive molecules into human cells for both therapeutic and R&D applications.

MaxCyte, previously known as TheraMed, Inc., is a biotechnology company which, after the recapitalisation in 2002, was launched as an independent company to effect a change of control from its parent company, EntreMed, Inc.

Douglas A. Doerfler, President and CEO
Judy Hedstrom, Senior Vice President Corporate and Business Development
Madhusudan Peshwa, Ph.D., Vice President, Research and Development
Joseph C. Fratantoni, MD, Vice President, Clinical Development and Medical Affairs
Ronald Holtz, CFO
Anthony Recupero, PhD, Vice President, Business Development

J. Stark Thompson, Ph.D., Chairman
Will Brooke
Douglas A. Doerfler
Stanley Erck
Chris Hegele
Arthur M. Mandell
Don Rainey

Michael R. Blaese, MD
Malcom Brenner, MD
Robert Gerety, MD, Ph.D.
Carl June, MD
Paul Ness, MD
James Weaver, Ph.D.

22 Firstfield Road, Suite 250
Gaithersburg, MD 20878
Phone: +1-301-944-1700
Fax: +1-301-944-1703

MaxCyte has developed a high-speed, sterile system to load cells with bioactive molecules including genes, drugs, and small molecules. The continuous flow cell loading technology is basically a reinvention of static electroporation, which uses electrical pulses to briefly make cell walls permeable. MaxCyte GT™ and flow cell can be used in therapeutic gene transfer, drug discovery, target validation and functional genomics. It uses blood cells instead of viral vectors to transport gene therapies to target sites. ErythroMax™ (Phase I) infuses red blood cells with a compound that can increase the amount of oxygen the cells carry and could be used during surgery or for patients suffering from various diseases.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.